Online citations, reference lists, and bibliographies.
← Back to Search

Antiretroviral-drug Resistance Among Patients Recently Infected With HIV.

S. Little, S. Holte, J. Routy, E. Daar, M. Markowitz, A. Collier, R. Koup, J. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. Whitcomb, N. Hellmann, D. Richman
Published 2002 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
BACKGROUND Among persons in North America who are newly infected with the human immunodeficiency virus (HIV), the prevalence of transmitted resistance to antiretroviral drugs has been estimated at 1 to 11 percent. METHODS We performed a retrospective analysis of susceptibility to antiretroviral drugs before treatment and drug-resistance mutations in HIV in plasma samples from 377 subjects with primary HIV infection who had not yet received treatment and who were identified between May 1995 and June 2000 in 10 North American cities. Responses to treatment could be evaluated in 202 subjects. RESULTS Over the five-year period, the frequency of transmitted drug resistance increased significantly. The frequency of high-level resistance to one or more drugs (indicated by a value of more than 10 for the ratio of the 50 percent inhibitory concentration [IC50] for the subject's virus to the IC50 for a drug-sensitive reference virus) increased from 3.4 percent during the period from 1995 to 1998 to 12.4 percent during the period from 1999 to 2000 (P=0.002), and the frequency of multidrug resistance increased from 1.1 percent to 6.2 percent (P=0.01). The frequency of resistance mutations detected by sequence analysis increased from 8.0 percent to 22.7 percent (P<0.001), and the frequency of multidrug resistance detected by sequence analysis increased from 3.8 percent to 10.2 percent (P=0.05). Among subjects infected with drug-resistant virus, the time to viral suppression after the initiation of antiretroviral therapy was longer (P=0.05), and the time to virologic failure was shorter (P=0.05). CONCLUSIONS The proportion of new HIV infections that involve drug-resistant virus is increasing in North America. Initial antiretroviral therapy is more likely to fail in patients who are infected with drug-resistant virus. Testing for resistance to drugs before therapy begins is now indicated even for recently infected patients.
This paper references
10.1056/NEJM199304223281605
Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1.
A. Erice (1993)
10.1056/NEJM199312163292502
Transmission from one child to another of human immunodeficiency virus type 1 with a zidovudine-resistance mutation.
J. Fitzgibbon (1993)
10.1093/INFDIS/169.2.411
Heterosexual transmission of human immunodeficiency virus type 1 variants associated with zidovudine resistance.
C. Conlon (1994)
10.7326/0003-4819-122-6-199503150-00001
Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy
R. D'Aquila (1995)
10.1093/CLINIDS/21.3.556
Transmission of zidovudine-resistant human immunodeficiency virus type 1 variants following deliberate injection of blood from a patient with AIDS: characteristics and natural history of the virus.
J. Veenstra (1995)
10.1097/00002030-199602000-00017
First case of new infection with zidovudine-resistant HIV-1 among prospectively studied intravenous drug users and homosexual men in Amsterdam, The Netherlands.
A. de Ronde (1996)
10.1126/SCIENCE.278.5341.1295
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy.
D. Finzi (1997)
10.1097/00002030-199709000-00016
Increase in the frequency of mutation at codon 215 associated with zidovudine resistance in HIV-1-infected antiviral-naive patients from 1989 to 1996.
A. Rubio (1997)
10.1086/516487
Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group.
A. Imrie (1997)
10.1126/SCIENCE.278.5341.1291
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
J. Wong (1997)
10.1126/SCIENCE.277.5322.112
Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease.
B. Autran (1997)
Mutations associated with zidovudine resistance in HIV-1 among recent seroconvertors.
M. Quigg (1997)
10.1056/NEJM199803263381301
Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.
F. Palella (1998)
10.1001/JAMA.280.1.42
New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes.
R. Janssen (1998)
10.1056/NEJM199807303390504
Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors.
F. Hecht (1998)
10.1097/00002030-199802000-00005
Induction of specific T‐cell responses in HIV infection
Ann-Charlotte Leandersson (1998)
10.1056/NEJM199812243392606
The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium.
S. Bozzette (1998)
10.1097/00002030-199817000-00009
Selective vertical transmission of HIV‐1 antiretroviral resistance mutations
R. Colgrove (1998)
10.1086/515591
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
M. Lederman (1998)
10.1001/JAMA.282.12.1135
HIV-1 drug resistance in newly infected individuals.
D. Bodén (1999)
10.1086/515225
Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
B. Conway (1999)
10.7326/0003-4819-131-11-199912070-00003
HIV-1 Genotypic Resistance Patterns Predict Response to saquinavirritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed
A. Zolopa (1999)
10.7326/0003-4819-131-7-199910050-00004
Drug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion
Stephanie Brodine (1999)
10.1097/00002030-199911120-00013
Recent increases in HIV seroconversion among repeat anonymous testers in San Francisco.
T. Kellogg (1999)
10.1001/JAMA.282.12.1142
Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
S. Little (1999)
10.1097/00002030-199902040-00001
Impact of drug resistance mutations on virologic response to salvage therapy. Swiss HIV Cohort Study.
P. Lorenzi (1999)
10.1016/S0140-6736(98)12262-6
Transmission of antiretroviral-drug-resistant HIV-1 variants
S. Yerly (1999)
10.1128/AAC.44.4.920-928.2000
A Novel Phenotypic Drug Susceptibility Assay for Human Immunodeficiency Virus Type 1
Christos J. Petropoulos (2000)
10.1177/135965350000500106
Prevalence of Transmitted Nucleoside Analogue-Resistant HIV-1 Strains and Pre-Existing Mutations in Pol Reverse Transcriptase and Protease Region: Outcome after Treatment in Recently Infected Individuals
C. Balotta (2000)
10.1001/JAMA.283.18.2417
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
M. Hirsch (2000)
10.1097/00002030-200001280-00003
Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use
H. Salomón (2000)
10.1128/JVI.74.22.10269-10273.2000
Reduced Susceptibility of Human Immunodeficiency Virus Type 1 (HIV-1) from Patients with Primary HIV Infection to Nonnucleoside Reverse Transcriptase Inhibitors Is Associated with Variation at Novel Amino Acid Sites
Andrew J. Leigh Brown (2000)
10.1001/JAMA.283.3.381
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
C. Carpenter (2000)
10.1086/320697
Vertical transmission of multidrug-resistant human immunodeficiency virus type 1 (HIV-1) and continued evolution of drug resistance in an HIV-1-infected infant.
V. Johnson (2001)
10.7326/0003-4819-135-1-200107030-00005
Highly Active Antiretroviral Therapy Decreases Mortality and Morbidity in Patients with Advanced HIV Disease
Edward Murphy (2001)
10.1097/00002030-200111230-00010
Acute HIV infection: impact on the spread of HIV and transmission of drug resistance
S. Yerly (2001)
10.1073/pnas.241300698
Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons
J. G. García-Lerma (2001)
10.1177/135965350100600103
Laboratory Guidelines for the Practical Use of HIV Drug Resistance Tests in Patient Follow-Up
A. Vandamme (2001)
10.1016/S1386-6532(01)00178-0
Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants.
G. Kamkamidze (2001)
10.1097/00126334-200106010-00001
Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort.
B. Masquelier (2001)
10.1136/bmj.322.7294.1087
Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom
K. Porter (2001)



This paper is referenced by
PPA_A_308571 1177..1185
Esileman Abdela Muche (2021)
10.2147/PPA.S308571
Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting
Eden Abetu Mehari (2021)
10.3389/fcimb.2021.643953
Chitosan-Based Nanoparticles Against Viral Infections
Homa Boroumand (2021)
10.3390/nano10091645
Antiviral Potential of Nanoparticles—Can Nanoparticles Fight Against Coronaviruses?
S. Gurunathan (2020)
10.1080/17512433.2020.1782737
The crosstalk between antiretrovirals pharmacology and HIV drug resistance
A. Giacomelli (2020)
Emerging Themes in Epidemiology
R. Baggaley (2020)
10.3390/nano10061072
Nanomaterials and Nanotechnology-Associated Innovations against Viral Infections with a Focus on Coronaviruses
M. Nasrollahzadeh (2020)
10.1111/hiv.13038
Transmitted HIV‐1 drug resistance in a large international cohort using next‐generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study
J. Baxter (2020)
Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV
(2020)
10.1007/s00705-020-04606-6
Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017–2019)
Zhaojie Yang (2020)
10.1371/journal.pone.0235958
Pre-treatment drug resistance and HIV-1 genetic diversity in the rural and urban settings of Northwest-Cameroon
J. Fokam (2020)
10.3201/eid2610.191506
Drug Resistance Spread in 6 Metropolitan Regions, Germany, 2001–20181
M. Stecher (2020)
10.1016/j.ijid.2020.02.004
Shall i trust the report? Variable performance of Sanger sequencing revealed by deep sequencing on HIV drug resistance mutation detection.
Nan-Yu Chen (2020)
10.1093/cid/ciz372
Clinical impact and cost-effectiveness of genotype testing at HIV diagnosis in the United States.
E. Hyle (2019)
10.3389/fphar.2019.00578
The Pre-clinical Toolbox of Pharmacokinetics and Pharmacodynamics: in vitro and ex vivo Models
C. Herrera (2019)
10.1089/AID.2018.0239
Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
Jaime Soria (2019)
10.1128/AAC.00466-19
Novel Central Nervous System (CNS)-Targeting Protease Inhibitors for Drug-Resistant HIV Infection and HIV-Associated CNS Complications
Masayuki Amano (2019)
10.1016/j.bmcl.2019.03.049
Synthesis and biological evaluation of new HIV-1 protease inhibitors with purine bases as P2-ligands.
M. Zhu (2019)
Genotypic and Phenotypic Resistance Assays
(2019)
10.2217/nnm-2018-0364
G2-S16 sulfonate dendrimer as new therapy for treatment failure in HIV-1 entry inhibitors.
Ignacio Rodríguez-Izquierdo (2019)
10.1002/9781119413431.ch38
Studies of Medication Adherence
J. Lauffenburger (2019)
10.1097/QAI.0000000000002135
Effectiveness of Transmitted Drug Resistance Testing Before Initiation of Antiretroviral Therapy in HIV-Positive Individuals.
S. Lodi (2019)
10.1016/S2352-3018(19)30337-6
Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
M. Chung (2019)
10.1111/add.14857
What do HIV-positive drug users' experience tell us about their antiretroviral medications taking? An international integrated literature review.
Iris Szu-Szu Ho (2019)
10.1002/jia2.25194
Successes and challenges in optimizing the viral load cascade to improve antiretroviral therapy adherence and rationalize second‐line switches in Swaziland
David Etoori (2018)
10.1089/aid.2017.0295
Changes from 2000 to 2009 in the Prevalence of HIV-1 Containing Drug Resistance-Associated Mutations from Antiretroviral Therapy-Naive, HIV-1-Infected Patients in the United States
L. Ross (2018)
10.1038/nrd.2018.53
Chemical probes and drug leads from advances in synthetic planning and methodology
C. Gerry (2018)
10.2174/1570162X16666180910130112
Assessment of Transmitted HIV-1 Drug Resistance Mutations Using Ultra- Deep Pyrosequencing in a Turkish Cohort.
U. Sili (2018)
10.2147/DHPS.S143178
Predictors of non adherence to antiretroviral therapy at an urban HIV care and treatment center in Tanzania
R. Sangeda (2018)
10.1371/journal.pone.0205446
HIV-genetic diversity and drug resistance transmission clusters in Gondar, Northern Ethiopia, 2003-2013
Dawit A Arimide (2018)
A qualitative exploration of flourishing among individuals diagnosed with HIV/AIDS in South Africa
RL Tsotetsi (2018)
10.19080/CTCMI.2018.02.555596
Transmitted Drug Resistance in Hiv-1 Non-B Subtypes Newly Diagnosed Patient: Case Report
G. Brindicci (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar